CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Raloxifenedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00065767
NCT00065767Phase 3Completed
CompareCT.gov

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

University of Wisconsin, Madison·interventional·Posted Aug 4, 2003·Updated Oct 5, 2015

In Brief

A Phase 3 clinical trial evaluating Raloxifene for Alzheimer Disease. Completed, across 1 site.

Detailed Summary

The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 4, 2003
Enrollment StartSep 1, 2001
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 22.9 years ago

Interventions

Raloxifenedrug